Eli Lilly Partners With Superluminal For AI-Driven Obesity Drugs

Eli Lilly has entered a $1.3 billion deal with Superluminal Medicines to develop AI-driven small-molecule drugs for obesity and cardiometabolic diseases. The partnership aims to bolster Lilly's position in the obesity treatment market, which is expected to reach $150 billion in the next decade. The deal includes upfront and milestone payments, equity stakes, and tiered royalties based on net sales. Lilly has faced challenges in the obesity drug market, including legal issues and trial setbacks, but this partnership could help the company regain its footing.